Drug Trial Radar · NCT06403735
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Apr 25, 2024
Primary completion
May 31, 2026
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
QLC1101 is a selective reversible inhibitor of KRAS G12D, with the dosage form of capsules and administration route of oral administration. In the first-in-humans (FIH) study, the sponsor will explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of QLC1101 in subjects with advanced solid tumors harboring a KRAS G12D mutation. The FIH study includes dose escalation, PK expansion, and efficacy expansion.
Conditions
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Solid Tumor
Interventions
QLC1101Drug
QLC1101 is an innovative small molecule inhibitor targeting KRAS G12D with independent intellectual property rights developed by Qilu Pharmaceutical Co., Ltd.QLC1101 can prevent GTP/GDP nucleotide exchange and/or the formation of KRAS G12D/GTP/RAF1 complex and inhibit mutant KRAS-dependent signal transduction by specifically binding to the KRAS G12D target, thereby inhibiting the generation of KRAS G12D mutant tumors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: 25 days after the first dose
- MTD (or MAD)Time frame: 1 year
- RP2DTime frame: 1.5 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China · Not yet recruiting
Harbin Medical university cancer hospital
Harbin, Heilongjiang, China · Not yet recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Shanghai east hospital
Shanghai, Shanghai Municipality, China · Recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.